Relay Therapeutics

AACR 2023 – Moderna's immunotherapeutic splash
AACR 2023 – Moderna's immunotherapeutic splash
EP Vantage
AACR
Moderna Therapeutics
Allogene
AstraZeneca
Merck
Roche
Novartis
Eli Lilly
Innovent
Springworks
Biogene
Relay Therapeutics
Vivace Therapeutics
Flag link:
JPM Day 2: Highlights
JPM Day 2: Highlights
BioSpace
JPMHC 2023
Relay Therapeutics
Sanofi
Scholar Rock
SAGE Therapeutics
Karuna Therapeutics
GSK
Flag link:
ESMO 2022 movers – KRAS backfires
ESMO 2022 movers – KRAS backfires
EP Vantage
ESMO
KRAS inhibitors
Relay Therapeutics
Regeneron
Amgen
Deciphera
Clovis Oncology
Ayala Pharmaceuticals
Springworks
Mirati Therapeutics
Flag link:
Relay kicks off public offering, seeking $300M on heels of robust ESMO data
Relay kicks off public offering, seeking $300M on heels of robust ESMO data
Endpoints
ESMO
Relay Therapeutics
funding
Flag link:
ESMO: Relay spotlights expanded FGFR2 inhibitor data it hopes will pave accelerated approval
ESMO: Relay spotlights expanded FGFR2 inhibitor data it hopes will pave accelerated approval
Fierce Biotech
ESMO
Relay Therapeutics
RLY-4008
cholangiocarcinoma
Flag link:
Relay Therapeutics’ Liver Cancer Approach Paying Early Dividends
Relay Therapeutics’ Liver Cancer Approach Paying Early Dividends
BioSpace
Relay Therapeutics
RLY-4008
intrahepatic cholangiocarcinoma
liver cancer
Flag link:
Biotech M&A tracker: After hitting new heights, deals have slowed down. Here are the latest.
Biotech M&A tracker: After hitting new heights, deals have slowed down. Here are the latest.
BioPharma Dive
M&A
Bayer
Sanofi
Amgen
uniQure
MorphoSys
Xeris Pharmaceuticals
Relay Therapeutics
Merck
Beam Therapeutics
Jazz Pharmaceuticals
Flag link:
In one of their first ever acquisitions, Relay bets $85M cash on a new AI-based screening approach
In one of their first ever acquisitions, Relay bets $85M cash on a new AI-based screening approach
Endpoints
Relay Therapeutics
M&A
ZebiAI
artificial intelligence
drug discovery
Flag link:
Genentech pays Relay $75M for cancer drug, plans KRAS combo
Genentech pays Relay $75M for cancer drug, plans KRAS combo
Fierce Biotech
Genentech
Relay Therapeutics
Roche
KRAS inhibitors
Flag link:
Another huge quarter for biotech flotations
Another huge quarter for biotech flotations
EP Vantage
biotech
IPOs
AlloVir
Relay Therapeutics
Nykarta
Dyne Therapeutics
Annexon Biosciences
Flag link:
Relay Therapeutics prices IPO at $400M
Relay Therapeutics prices IPO at $400M
MedCity News
Relay Therapeutics
IPOs
drug discovery
Flag link:
Another four biotechs scratch out the first number and ask for more as IPO boom continues
Another four biotechs scratch out the first number and ask for more as IPO boom continues
Endpoints
IPOs
biotech
Relay Therapeutics
Nkarta Therapeutics
Poseida Therapeutics
Inventiva
Flag link:
Relay Lays $200M IPO Plan to Fund Tests of Protein Motion Cancer Drugs
Relay Lays $200M IPO Plan to Fund Tests of Protein Motion Cancer Drugs
Xconomy
Relay Therapeutics
IPOs
protein motion
cancer
Flag link:
Where Are They Now? Top 3 Biotech Startups From NextGen Bio Class of 2018
Where Are They Now? Top 3 Biotech Startups From NextGen Bio Class of 2018
BioSpace
Blue Rock Therapeutics
Prelude Fertility
Relay Therapeutics
Flag link:
Relay Therapeutics Banks $400 Million in Series C Round
Relay Therapeutics Banks $400 Million in Series C Round
CP Wire
Relay Therapeutics
drug discovery
cancer
Flag link:
Relay Therapeutics Banks $400 Million in Series C Round
Relay Therapeutics
Flag link: